Message from President

Seikagaku will move forward steadily on implementing high-priority strategies in the mid-term management plan to develop as a “Global Category Pharma.”

 On the basis of the Seikagaku Corporation Ten-Year Vision, Seikagaku is focusing its research and development on glycoscience with the aim of developing as an internationally competitive “Global Category Pharma.” As part of this effort, we are currently implementing high-priority strategies in the mid-term management plan (from fiscal 2016 to fiscal 2018) with the key concept “ACT for the Vision—Achieving the Ten-Year Vision and Making a Further Leap Forward.” 

 With regard to SI-6603(*1), a development theme that is key to the growth strategy, we will continue efforts to obtain regulatory approval in Japan, where the NDA is under review. In the U.S., where SI-6603 failed to meet its primary endpoint in a Phase III clinical trial, we will proceed with preparations to initiate a new trial as quickly as possible. Clinical trials are progressing for indications for SI-613(*2), for which we have concluded a formal agreement for co-development and marketing collaboration in Japan with Ono Pharmaceutical Co., Ltd., and we will make every effort to obtain early approval for its use by patients.


*1 SI-6603:A treatment for lumbar disc herniation

*2 SI-613:A treatment for osteoarthritis and enthesopathy

Improving Shareholder Value

We are working to improve shareholder value through the evolution of Seikagaku as a "Global Category Pharma." Our management policies will also continue to emphasize the maintenance of confidence in Seikagaku.

Seikagaku strives to increase shareholder value through sustained growth. In the coming years, we will continue to seek the trust of all our stakeholders including shareholders.
We look forward to the continuing support and understanding of our stakeholders including shareholders.

December 2017
Ken Mizutani